Form 4: Arcutis EVP Sells Shares After Option Exercise

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, exercised stock options and subsequently sold 11,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc., engaged in transactions involving the company's common stock.
• On December 15, 2025, Burnett acquired 11,500 shares of common stock by exercising stock options at a price of $3.64 per share.
• Immediately following the option exercise on December 15, 2025, Burnett sold 11,500 shares of common stock at a weighted average sale price of $28.9436 per share.
• The sale price ranged from $28.61 to $29.20 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
• Following these transactions, Burnett directly beneficially owns 98,307 shares of common stock.
• Burnett also beneficially owns 143,750 derivative securities in the form of stock options.
• A scrivener's error on a previous Form 4 filed on November 5, 2025, which overstated beneficial ownership by 18 shares, has been corrected in this filing.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of filing is generally neutral in sentiment as it reflects a planned liquidity event rather than a direct signal of positive or negative company performance or outlook.

Positives

• The reporting person realized a significant gain by selling shares at a weighted average price of $28.9436 after exercising options at $3.64, indicating a profitable transaction for the insider.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be perceived negatively by some investors as it reduces the executive's direct equity stake in the company.

Risks

• No specific risks to the company's operations or financial health were mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The filing indicates that the reported transactions were part of a pre-arranged 10b5-1 trading plan, which is scheduled to conclude on February 27, 2026. This suggests that further transactions under this specific plan may occur until that date, subject to the plan's terms.

Management Comments

• The transactions were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
• The price reported for the sale is a weighted average, with shares sold in multiple transactions ranging from $28.61 to $29.20.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology industry. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing an affirmative defense against insider trading allegations. Such transactions are generally viewed as routine liquidity events rather than signals of management's sentiment about the company's future, especially when part of a long-standing plan.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance, providing transparency and mitigating concerns about opportunistic insider trading, a standard practice among executives in publicly traded companies, including those in the biotech sector.
• The exercise of options and subsequent sale of shares is a common method for executives to realize value from their equity compensation, comparable to practices observed at other biotech firms where executives monetize vested options.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, while planned, slightly reduces the executive's direct alignment with shareholder interests through equity ownership. However, the pre-planned nature mitigates concerns of opportunistic selling.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The 10b5-1 trading plan adopted on December 12, 2024, is set to continue until its end date of February 27, 2026, implying potential for further planned transactions by the reporting person.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Transaction, Biotechnology